|
Name |
palmarumycin CP2
|
Molecular Formula | C20H14O4 | |
IUPAC Name* |
8-hydroxyspiro[2,3-dihydronaphthalene-4,3'-2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene]-1-one
|
|
SMILES |
C1CC2(C3=C(C1=O)C(=CC=C3)O)OC4=CC=CC5=C4C(=CC=C5)O2
|
|
InChI |
InChI=1S/C20H14O4/c21-14-7-3-6-13-19(14)15(22)10-11-20(13)23-16-8-1-4-12-5-2-9-17(24-20)18(12)16/h1-9,21H,10-11H2
|
|
InChIKey |
BGMMZNMDIABGHL-UHFFFAOYSA-N
|
|
Synonyms |
palmarumycin CP2; CHEMBL511169; SCHEMBL10000180; 8-hydroxyspiro[2,3-dihydronaphthalene-4,3'-2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene]-1-one
|
|
CAS | NA | |
PubChem CID | 9995992 | |
ChEMBL ID | CHEMBL511169 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 318.3 | ALogp: | 4.4 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 55.8 | Aromatic Rings: | 5 |
Heavy Atoms: | 24 | QED Weighted: | 0.65 |
Caco-2 Permeability: | -4.924 | MDCK Permeability: | 0.00001880 |
Pgp-inhibitor: | 0.052 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0.04 |
Blood-Brain-Barrier Penetration (BBB): | 0.465 | Plasma Protein Binding (PPB): | 97.67% |
Volume Distribution (VD): | 0.621 | Fu: | 1.14% |
CYP1A2-inhibitor: | 0.952 | CYP1A2-substrate: | 0.264 |
CYP2C19-inhibitor: | 0.945 | CYP2C19-substrate: | 0.088 |
CYP2C9-inhibitor: | 0.912 | CYP2C9-substrate: | 0.934 |
CYP2D6-inhibitor: | 0.793 | CYP2D6-substrate: | 0.349 |
CYP3A4-inhibitor: | 0.853 | CYP3A4-substrate: | 0.263 |
Clearance (CL): | 5.29 | Half-life (T1/2): | 0.521 |
hERG Blockers: | 0.017 | Human Hepatotoxicity (H-HT): | 0.336 |
Drug-inuced Liver Injury (DILI): | 0.937 | AMES Toxicity: | 0.959 |
Rat Oral Acute Toxicity: | 0.707 | Maximum Recommended Daily Dose: | 0.069 |
Skin Sensitization: | 0.671 | Carcinogencity: | 0.951 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.869 |
Respiratory Toxicity: | 0.702 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002530 | 0.753 | D06TJJ | 0.352 | ||||
ENC003199 | 0.753 | D08CCE | 0.287 | ||||
ENC005582 | 0.707 | D05VLS | 0.269 | ||||
ENC001112 | 0.707 | D0H8QL | 0.267 | ||||
ENC005583 | 0.682 | D06ZEE | 0.263 | ||||
ENC005524 | 0.682 | D0QV5T | 0.262 | ||||
ENC000996 | 0.667 | D0Q5UQ | 0.261 | ||||
ENC005548 | 0.655 | D02TJS | 0.259 | ||||
ENC003201 | 0.602 | D0L6DA | 0.257 | ||||
ENC002038 | 0.565 | D0O6IZ | 0.255 |